Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.44 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.44 |
| ▸ | AKT1 | P31749 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31656330 | 0.81 | OPRD1 (0.61) | OPRD1OPRM1NMUR2NMUR1 | |
| SCHEMBL12122107 | 0.77 | TSG101 (0.54) | — | |
| SCHEMBL29377612 | 0.76 | DPP4 (0.43) | OPRD1OPRM1ITGB1ITGA4ACE | |
| SCHEMBL14599754 | 0.76 | MMP3 (0.58) | OPRD1OPRM1MMP1MMP3NMUR2 | |
| SCHEMBL5551658 | 0.76 | MMP3 (0.58) | OPRD1OPRM1MMP1MMP3NMUR2 | |
| SCHEMBL23710235 | 0.75 | NMUR2 (0.44) | OPRD1OPRM1NMUR2NMUR1 | |
| SCHEMBL31511428 | 0.74 | OPRD1 (0.58) | OPRD1OPRM1NMUR2NMUR1 | |
| SCHEMBL20306231 | 0.74 | XIAP (0.51) | OPRD1OPRM1ACENMUR2NMUR1 | |
| SCHEMBL6852479 | 0.73 | NMUR2 (0.54) | OPRD1OPRM1NMUR2NMUR1 | |
| SCHEMBL18270523 | 0.72 | OPRM1 (0.52) | OPRD1OPRM1NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556014-B2 | Compounds containing a vascular disrupting agent | ELLIPSES PHARMA LIMITED (GB) | 2020-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556014-B2 | Compounds containing a vascular disrupting agent | MMP10, MMP11, MMP3 | OPRD1 4568/4885OPRM1 4736/4885ITGB1 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.